TheraRadar
← Back
Data updated: Jun 28, 2026

KINDOS

Generics

KINDOS is a generic drug manufacturer focused on Infectious Disease, Oncology, Dermatology.

2024
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

KINDOS's Key Drugs

KINDOS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

KINDOS's Recent FDA Approvals

New NDA/BLA approvals for KINDOS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

KINDOS's Therapeutic Areas

KINDOS's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
2 drugs
Oncology 25%
1 drugs
Dermatology 25%
1 drugs

KINDOS's Top Competitors

KINDOS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and KING PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

KINDOS Pipeline Snapshot

Active clinical trials for KINDOS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling